Orforglipron vs Retatrutide
Extensively Studied vs Extensively Studied
monitor Mechanism-based · 50% Both Orforglipron and Retatrutide promote fat breakdown. While additive fat loss is possible, excessive lipolysis can cause rapid free fatty acid elevation and cardiac strain. Monitor heart rate and adjust doses gradually.
Molecular Data
Orforglipron Retatrutide
Weight 882.974 Da 4,731.33 Da
Half-life 25-68 hours ~6 days
Chain Non-peptide small molecule 39 amino acids
Type Small-molecule GLP-1R agonist Triple GLP-1/GIP/glucagon agonist
Key Benefits
Orforglipron
01 Significant weight loss (up to 12.4% at 72 weeks)
02 Robust diabetes control (HbA1c reduction 1.3-1.6%)
03 Once-daily oral tablet format
04 No refrigeration or food restrictions required
05 Reduced cardiovascular risk markers
Retatrutide
01 Superior weight loss (24.2% at 48 weeks)
02 Improved glycemic control (HbA1c reduction up to 2.16%)
03 Enhanced cardiovascular benefits
04 Hepatic fat reduction (up to 82%)
05 Triple mechanism addresses obesity through multiple pathways
Dosing Protocols
Orforglipron
Start 3-6mg daily, titrate up to 12-36mg based on response / Once daily oral tablet
Retatrutide
0.5mg starting, titrate up to 8-12mg weekly / Once weekly (same day each week)
Starting Dose (Week 1-4) 0.5mg Once weekly
Low Maintenance (Week 4-8) 1mg Once weekly
Escalation (Week 8-12) 2mg Once weekly
Moderate (Week 12-16) 4mg Once weekly
Advanced (Week 16-20) 8mg Once weekly
Maximum Efficacy (Week 20+) 12mg Once weekly
Side Effects
Orforglipron
Diarrhea (more prevalent than with injectable GLP-1s)
Nausea (typically improves after first month)
Appetite reduction
Retatrutide
Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
Heart rate increases—common especially in first 24 weeks
Appetite suppression
Mild dehydration
Contraindications
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy and breastfeeding
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Research Evidence
Orforglipron Retatrutide
Status Extensively Studied Extensively Studied
References 4 studies 6 studies
Latest — 2025-10
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.